De Fazio S R, Gozzo J J, Monaco A P
Cancer Res. 1982 Jul;42(7):2913-7.
Previous work in our laboratory has demonstrated that antisera to proteins found in the urine of bladder cancer patients can distinguish between urine samples from these patients and those from normal individuals when tested by a complement-fixation assay. Antisera which were reactive with individual tumor-associated antigens were used to detect the antigens in the urine of bladder cancer patients and control individuals. One antigen was found in 66% of the bladder cancer patients (n = 38) and 25% of control individuals (n = 20). This antigen is a glycoprotein with a molecular weight of about 200,000 and beta-electrophoretic mobility and is distinct from carcinoembryonic antigen. A second molecule detected by an antiserum to urine fractions proved to be completely identical to serum C-reactive protein. C-Reactive protein was found in the urine of 72% of the bladder cancer patients (n = 39) and 32% of the control population (n = 32). Although a third protein detected with these antisera proved to be a normal urinary component, two of these tumor-related proteins appear to have potential as diagnostic markers for bladder cancer.
我们实验室之前的研究表明,针对膀胱癌患者尿液中发现的蛋白质的抗血清,在通过补体结合试验检测时,能够区分这些患者与正常个体的尿液样本。与单个肿瘤相关抗原发生反应的抗血清被用于检测膀胱癌患者和对照个体尿液中的抗原。在66%的膀胱癌患者(n = 38)和25%的对照个体(n = 20)中发现了一种抗原。这种抗原是一种糖蛋白,分子量约为200,000,具有β电泳迁移率,且与癌胚抗原不同。通过针对尿液组分的抗血清检测到的第二种分子被证明与血清C反应蛋白完全相同。在72%的膀胱癌患者(n = 39)和32%的对照人群(n = 32)的尿液中发现了C反应蛋白。尽管用这些抗血清检测到的第三种蛋白质被证明是一种正常的尿液成分,但其中两种与肿瘤相关的蛋白质似乎有作为膀胱癌诊断标志物的潜力。